Business Description
Pulse Biosciences Inc
NAICS : 339113
SIC : 3841
ISIN : US74587B1017
Total Employee Number:
116Description
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 15.01 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | -0.08 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 117.7 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -37 | |||||
3-Year EBITDA Growth Rate | 11.8 | |||||
3-Year EPS without NRI Growth Rate | 13.9 | |||||
3-Year FCF Growth Rate | 16.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -7.42 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 268.82 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 76.93 | |||||
9-Day RSI | 77.16 | |||||
14-Day RSI | 75.81 | |||||
3-1 Month Momentum % | 14.95 | |||||
6-1 Month Momentum % | 14.35 | |||||
12-1 Month Momentum % | 80.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.63 | |||||
Quick Ratio | 9.61 | |||||
Cash Ratio | 9.26 | |||||
Days Inventory | 42.37 | |||||
Days Sales Outstanding | 43.74 | |||||
Days Payable | 870.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21.5 | |||||
Shareholder Yield % | -1.34 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 0.25 | |||||
Operating Margin % | -7007.76 | |||||
Net Margin % | -6755.78 | |||||
EBITDA Margin % | -6921.35 | |||||
FCF Margin % | -5180.42 | |||||
OCF Margin % | -5155.95 | |||||
ROE % | -90.23 | |||||
ROA % | -76.87 | |||||
ROIC % | -523.85 | |||||
3-Year ROIIC % | 443.97 | |||||
ROC (Joel Greenblatt) % | -1175.77 | |||||
ROCE % | -87.71 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2762.94 | |||||
PB Ratio | 33.43 | |||||
Price-to-Tangible-Book | 34.54 | |||||
EV-to-EBIT | -39.2 | |||||
EV-to-EBITDA | -39.69 | |||||
EV-to-Revenue | 2746.98 | |||||
EV-to-Forward-Revenue | 1251.75 | |||||
EV-to-FCF | -53.03 | |||||
| Price-to-Net-Current-Asset-Value | 36.98 | |||||
| Price-to-Net-Cash | 38.82 | |||||
Earnings Yield (Greenblatt) % | -2.55 | |||||
FCF Yield % | -1.83 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PLSE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pulse Biosciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.185 | ||
| EPS (TTM) ($) | -1.18 | ||
| Beta | 2.9825 | ||
| 3-Year Sharpe Ratio | 0.89 | ||
| 3-Year Sortino Ratio | 2.08 | ||
| Volatility % | 51.36 | ||
| 14-Day RSI | 75.81 | ||
| 14-Day ATR ($) | 2.838617 | ||
| 20-Day SMA ($) | 39.33875 | ||
| 12-1 Month Momentum % | 80.83 | ||
| 52-Week Range ($) | 12.56 - 48.84 | ||
| Shares Outstanding (Mil) | 71.32 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pulse Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pulse Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-19 16:30 | In 184 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-19 | In 183 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 16:30 | In 78 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 77 days | ||
| Canaccord Genuity’s 46th Annual Growth Conference | 2026-08-11 14:30 | 41.51 (-2.95%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 16:30 | 37.90 (-1.12%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 37.90 (-1.12%) | ||
| General meeting for 2026 | 2026-06-11 11:00 | 24.99 (+1.96%) | ||
| Guidance call for 2026 | 2026-06-10 10:00 | 25.77 (+3.66%) | ||
| Guidance call for 2026 | 2026-05-13 16:35 | 23.30 (+12.07%) |
Show
Entries
Pulse Biosciences Inc Frequently Asked Questions
What is Pulse Biosciences Inc(PLSE)'s stock price today?
The current price of PLSE is $46.97. The 52 week high of PLSE is $48.84 and 52 week low is $12.56.
When is next earnings date of Pulse Biosciences Inc(PLSE)?
The next earnings date of Pulse Biosciences Inc(PLSE) is 2026-11-05 Est..
Does Pulse Biosciences Inc(PLSE) pay dividends? If so, how much?
Pulse Biosciences Inc(PLSE) does not pay dividend.
Guru Commentaries on NAS:PLSE
No articles.
Press Release
Articles on Pulse Biosciences Inc
Pulse Biosciences (PLSE) Grants Equity Awards to New Hires Amid High Price-to-Sales Valuation
2 days ago
PLSE Virtual Meeting on Strategic Initiatives Highlights Growth Expectations Despite High Valuation
4 days ago
Headlines
See More- 1
Aug 07, 2026
Pulse Biosciences targets early October enrollment completion for 164-patient NANOPULSE-AF study
Seeking Alpha • 4:45am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers